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In pursuit of precision medicine in the critically ill 
 “For it is not enough to recognize that all our knowledge is, in a greater or less 
degree, uncertain and vague; it is necessary, at the same time, to learn to act upon 
the best hypothesis without dogmatically believing it.” From, Philosophy for Laymen, 
by Bertrand Russell. 
Introduction 
Critical care medicine is, at present, a specialty of broad syndromes. This 
reflects the similarity in therapeutic approach required for the final common 
physiology that follows from many different pathological processes. Since their 
original definitions and descriptions, sepsis and acute respiratory distress syndrome 
(ARDS) are the two clinical conditions that have shaped health policy and dominated 
the research agenda in critical care[1, 2]. It is a truism to state that these are 
conglomerates of numerous different sub-syndromes; to make this observation is 
simply to restate the definition of sepsis and ARDS as common patterns arising from 
numerous different injuries. But it is also clear that, if we take the simple example of 
organ failure arising from a sterile versus an infectious insult, there is a very high 
likelihood that patients will respond differently to treatment with antibiotics. Or to take 
a more ambitious example, if we could diagnose, at presentation, the infectious 
agent causing sepsis, we could then confidently treat with narrow spectrum 
antibiotics. In this way, sub-classifications of critical illness are almost certainly 
directly applicable to clinical practice. 
With numerous statistically negative randomized controlled trials reported in 
both sepsis and ARDS, and strong conceptual arguments that patients presenting 
with these two conditions are heterogeneous, the idea of providing clinical care 
based on some patient level characteristic, along similar lines highlighted in cancer 
medicine is very appealing. Thus, critical care is contemplating approaches that are 
considered useful in cancer medicine, and other clinical fields such as respiratory 
medicine, to inform clinical trials in sepsis and ARDS. However, the challenges with 
precision medicine in the critically ill could be related to the classic paper by Geoffrey 
Rose – Sick Individuals and Sick Populations[3]. The key principle is that individual 
and population approaches to improving health achieve different aims; the individual 
approach aims to protect susceptible (high-risk) patients, whilst the population 
approach aims to reduce the group level incidence of or outcome from diseases. In 
this short perspective, after discussing the rationale for current definitions, we 
discuss whether the heterogeneity and precision medicine concepts could inform 
future studies in sepsis and/or ARDS. 
Rationale for ARDS and sepsis definitions with predictive validity 
The latest ARDS[2] and sepsis definitions[1] and the corresponding clinical criteria[4-
6] were derived to identify patient populations with predictive validity, by combining 
the consensus conference discussions with empirical evaluation of clinical data; 
resulting in valid and reliable critical illness syndromic definitions. ARDS is defined 
as acute onset hypoxic respiratory failure despite a positive end expiratory pressure 
of 5 or greater, with non-cardiogenic pulmonary edema evidenced by bilateral chest 
opacities. With this definition, stages of mild, moderate, and severe ARDS based on 
severity of hypoxemia, were associated with significantly higher mortality and 
increased median duration of mechanical ventilation in survivors[2]. Sepsis is defined 
as life-threatening organ dysfunction caused by a dysregulated host response to 
infection, with organ dysfunction defined as an increase in the Sequential [Sepsis-
related] Organ Failure Assessment (SOFA) score of 2 points or more[4]. Septic 
shock was defined as a subset of sepsis in which profound circulatory, cellular, and 
metabolic abnormalities are associated with a greater risk of mortality than with 
sepsis alone. Patients with septic shock can be clinically identified by a vasopressor 
requirement to maintain a mean arterial pressure of 65 mm Hg or greater and serum 
lactate level greater than 2mmol/L in the absence of hypovolemia[5]. With this 
definition, sepsis and septic shock were associated with significantly higher mortality, 
compared to uncomplicated infection[1]. The predictive validity for mortality 
categories could potentially inform clinical care and trial design. For example, 
worsening ARDS severity has been aligned with treatment options, with severe 
ARDS aligned with need for neuromuscular blockade, prone position and 
extracorporeal support[6]. 
Heterogeneity 
Heterogeneity is the inter-individual variation in susceptibility to either the illness or 
the outcome from illness or both. When risk factors for the illness or outcome are 
reported, the unstated (and likely incorrect) assumption is that these risk factors 
confer similar risk to individuals in a population, which is often overlooked during 
design, conduct and interpretation of studies [7].  Variation in the risk of illness or 
outcome is generated either as a random phenomenon, or due to measurable 
differences in biological characteristics in patients [8, 9], resulting from genetic 
and/or environmental influences. It is challenging to discern the relative contribution 
of each of these influences on outcomes in a critically ill ARDS or sepsis patient. For 
contextualization to ARDS and sepsis patients, heterogeneity could be categorized 
in patient, illness biology and treatment response level differences. 
Patient level heterogeneity 
Patient level heterogeneity contemplates broadly two questions – (a) why did this 
patient get this disease at this time? [3] and (b) why did this patient have a different 
outcome, compared to another patient who appeared similar in many aspects of 
illness? The answer to these questions rely on understanding the determinants of 
susceptibility amongst individuals to the illness (risk of illness) and the illness related 
outcomes (risk of outcome). For example, as sepsis is infection related organ 
dysfunction, the risk factors for sepsis would include risk factors for infection and risk 
factors for developing organ dysfunction in the context of infection. The risk factors 
for developing organ dysfunction in the context of infection is poorly understood. The 
risk factors for infection include age with an inverted parabolic distribution with 
highest risk at extremes of age, male sex, ethnicity with black race and Asians with a 
higher risk and presence of one or comorbidity[10].  
Genetic predisposition to infectious diseases is strongly heritable[11, 12], 
presumably due to the strong selective pressure exerted by pathogens on our 
ancestors. Identifying – and understanding – the genetic factors underlying 
predisposition may lead directly to tractable therapeutic targets in the host[13]. 
Several strong associations with susceptibility to infections have been discovered 
(e.g. HIV, WNV, TB, Malaria, Flu, meningococcus)[14-16], but these tend to be 
highly pathogen-specific. Whether there is general genetic susceptibility to sepsis, or 
even more broadly to a deleterious response to sterile injury, remains an open 
question. However, several lines of evidence suggest that responses to critical 
illness are likely to exhibit heritable variation in human populations. Firstly, the 
consensus in critical care medicine, supported by many years of clinical and animal 
model research, is that organ failure seen during critical illness is complex, driven by 
immune-mediated injury and alterations in bioenergetics [17, 18], alongside 
individual predisposition discussed as patient heterogeneity. Immune phenotypes 
tend to be strongly heritable, and numerous genetic associations for both 
autoimmune and infectious diseases have been discovered. Importantly, many of 
these disease associations are pleiotropic[19]. Hence, variation in the host 
responses to severe systemic injury is likely to be in part genetically-determined. 
Finally, and most directly, the results of the GAINS and GenoSept studies have 
discovered some genetic associations with outcome in sepsis [20], which will be 
important candidates for further biological investigation. 
Similarity within sepsis and ARDS biological heterogeneity 
Acute immune changes in sepsis, studied using whole blood transcriptomics, 
identifies a complex set of pro and anti-inflammatory abnormalities in the innate and 
adaptive immune systems and alteration in genes highlighting mitochondrial 
dysfunction [21]. Ability of antigen presenting cells such as dendritic cells, 
monocytes-macrophage system, follicular dendritic cells are impaired and there is 
accelerated depletion of B and T lymphocytes. When the same biology is studied by 
looking for unsupervised clustering algorithms, between 2 and 4 different 
subphenotypes within sepsis have been observed [18, 22-25]. At clinical 
characteristics level, site of infection, numbers of organ dysfunction, type of organ 
dysfunction and combination of organ dysfunctions also influence outcome from 
sepsis and add to this heterogeneity [26]. In ARDS, the structural and functional 
disruption of the alveolar endothelial and epithelial barrier, result from generation of 
inflammasome and signalosome complexes, by leukocyte sensing of danger signals  
[27, 28]. The endothelial abnormalities and inflammatory responses observed in 
ARDS are also seen in sepsis and trauma [23, 29]. Furthermore, ARDS patients 
could also be grouped into hyperinflammatory and non-reactive ARDS 
subphenotypes based on biomarkers and/or clinical variables [30-34] (Table-1). 
Heterogeneity in treatment responses 
For any treatment, the essential drivers arguing for a precision medicine approach, 
either in clinical setting or trial setting, include the between patient differences in 
treatment responses, patient-level interaction with treatment due to individual 
heterogeneity and the variation in treatment response determined by stage of illness 
due to variability in the lag time between onset of illness to treatment [35]. A simple 
example for the impact of time on treatment effect is the relationship between time to 
antibiotic treatment and outcome. In a cohort study, Seymour et al, highlighted that in 
patients who had the 3-hour Surviving Sepsis Campaign Bundle (blood culture, 
antibiotic therapy and measure lactate) completed within a 12-hour period, every 
extra hour taken to complete the bundle is associated with a significant increase in 
mortality [36]. Similarly, treatment effect of drugs has been shown to vary with illness 
severity, using activated protein C trials in sepsis and effect of PEEP in ARDS [37] 
as examples. A related concept in this context is heterogeneity in treatment 
response, which is a crude omnibus test for differences in responses to treatment 
and illness related outcomes arising from all factors contributing to heterogeneity and 
stochasticity of risk. This has been illustrated using simulation of sepsis and ARDS 
RCTs [38] and by using completed RCT data from intravenous immunoglobulin trials 
in sepsis [39]. As the risk of death changes in a trial population, the differences in 
mortality between the intervention arm and the usual arm also changes. This could 
potentially highlight a risk of outcome specific sub-group within ARDS and sepsis 
who are likely to benefit the most from the intervention. 
Stratified medicine and enrichment 
Stratified medicine refers to identifying groups of patients based on either 
characteristics of disease, or likely treatment response at a population levels. 
Enrichment markers are biomarkers that help identify either treatment responders 
and/or patients with higher risk of certain outcomes[40]. Thus, in the context of 
sepsis and ARDS, stratified medicine (enrichment) of clinical trial populations is a 
potentially viable strategy, as differential biological mechanisms and the technical 
ability to prospectively identify patient subsets exist. For example, in children with 
septic shock, using a 100-gene profile and serum protein biomarkers, it is possible to 
identify two patient subsets, with different outcomes, and differential responses to 
corticosteroid treatment [41]. Similarly, in adults with septic shock, corticosteroid 
responders can be identified using a three-biomarker panel [42]. Similarly, ARDS 
subsets, that respond differently to ventilator and fluid management, have been 
identified using data from completed ARDS trials [32, 33]. 
In 2007, Trusheim et al proposed three necessary conditions [40] required for 
effective stratified medicine for a disease: (a) differential biological mechanisms, (b) 
multiple treatment options, and (c) a clinical biomarker that links patient subsets to 
treatment responses. Sadly, in critical care medicine, we are a long way from 
meeting the second criterion: multiple treatment options.   
However, as efforts have progressed to achieve these goals, both in critical care 
medicine and beyond, it has become clear that a necessary first step is the 
identification of a pattern, or subgroup, within heterogeneous patient populations. In 
itself, this is purely an exercise of academic interest, but where a common biological 
mechanism can be found, there is a reasonable chance that some current or future 
therapy might have a different effect in patients belonging to a given subgroup - this 
essentially is the definition of a disease endotype [43]. The process of identifying 
endotypes is conceptually identical to the approach taken by our medical forebears: 
a syndrome becomes a disease when the underlying mechanism is thought to be 
known. Given the interplay of multiple mechanisms, two or more endotypes are likely 
in ARDS and sepsis. 
The identification of a disease endotype has immediate clinical relevance, since it is 
likely that patients with a given endotype will respond differently to some therapies 
when compared with patients having other patterns of disease. Once an endotype is 
convincingly discovered, considerable investment of academic and commercial 
resource is applied to identifying both treatments and viable biomarkers with which to 
make the diagnosis [44]. It is therefore important to consider carefully what criteria 
must be met for this enterprise to proceed. Differential response to therapy is 
probably too high a bar in critical care medicine, because in many cases the 
fundamental problem is that we lack specific diseases and therapies for those 
diseases. Thus, a major aspiration of this field is that, by better understanding the 
underlying biology, we may be able to create or repurpose drug treatments to 
modulate the host response to injury. At present, however, efforts to achieve this 
goal have failed. Aside from heterogeneity, this is not necessarily because of lack of 
understanding of molecular mechanisms involved, but due to the complex interplay 
of many mechanisms contributing to the final outcome, and targeting one particular 
mechanism may not yield the desired treatment benefit.  Progress in identifying 
distinct disease processes in critical illness should not be held back by this limitation.  
We therefore propose the following, permissive, criteria for concluding that a valid 
and reliable endotypes exist in critically ill populations. Subgroups should be: 
1. Consistency 
2. Biologically plausible 
3. Clinically plausible 
4. Feasibility of implementation in clinical care and/or trials 
Consistency can be measured using standard criteria for generalizability to other 
populations of similar patients. Where, as is often the case, expensive new 
technologies have been used to observe patterns in a group of patients, consistency 
must necessarily be determined within the original population, using a bootstrapping 
approach or similar. Plausibility is a vague and subjective concept but we contend 
that most investigators know it when they see it. Biological plausibility can – in some 
cases – be determined by statistical tests applied to the biological signature that 
defines membership of a subgroup. Such signatures may depend on systematic 
collections of known biology, for example for pathway enrichments, or genome-wide 
methods[45], such as co-expression module enrichment [46]. If the number of tests 
performed is faithfully reported, these approaches can provide convincing evidence 
that a given grouping is biologically real. Clinical plausibility is an extension of this 
concept. Biological plausibility has obvious limitations: there are many real 
subgroupings of any population of patients. Hence if there is not a predictable 
mechanism by which a given subgrouping could turn out to have a differential 
treatment effect, or at least a differential effect on prognosis, then the risk of failure is 
expected to be high. Finally, feasibility represents a compromise between the truth of 
detection (validity) and reliability of measurements to identify subgroups. For 
example, a cytokine profile for identifying corticosteroid responders in septic shock 
[42] could be considered to have greater feasibility compared to 100-gene 
expression panel [41], but with different reliability and validity. Importantly, it is 
possible, but not necessary, for clinical outcome to be different between endotypes: 
patients with different diagnoses can have identical statistical probabilities of a given 
outcome. A focus on outcome runs the risk of detecting severity markers, rather than 
distinct biological processes.  
Precision medicine 
Fundamentally, precision medicine represents a scenario where detecting one or 
more biological abnormalities in patients help pair them to treatment(s), based on the 
individuals’ favorable treatment response – adverse effect profile. Most precision 
medicine advances have been in oncology, although consistent success is limited. 
For example, super-responders to Everolimus treatment considered as exemplar for 
precision oncology [47] have not been consistently replicated. Furthermore, the 
cancer free survival amongst patients with relapse and/or refractory tumors is not 
impressive and super-responders to targeted chemotherapy may be a much smaller 
cancer population than previously considered [48]. For example, a recently published 
phase II multicenter RCT enrolled 741 adult patients with any kind of metastatic solid 
tumour refractory to standard of care. From this population, 40% of patients had at 
least one molecular alteration that matched with one of the 10 treatment regimens 
and 195 patients were randomized to receive experimental treatment specific for 
pathway mutations or standard of care. There were no differences in efficacy or 
adverse event end points between the intervention and control arms [49]. These 
lessons from precision oncology approaches must be seriously considered [50], 
when testing precision medicine in critically ill patients with heterogeneous 
syndromes such as sepsis or ARDS. 
Conclusions 
ARDS and sepsis often occur in older patients with comorbidity resulting in critical 
illness. Heritable characteristics and environmental factors influence the incidence 
and outcomes from ARDS and sepsis. We have begun to group ARDS and sepsis 
patients with similar biological characteristics and consider stratified or precision 
medicine as the solution for overcoming statistically negative clinical trials. Key 
biological and clinical plausibility challenges need to be addressed to achieve major 
breakthroughs in future trials and the clinical care of sepsis and ARDS patients.  
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Table-1: Recent studies describing Acute respiratory distress syndrome and sepsis subphenotypes 
Abbreviations: IL = interleukins; sTNFR1 = soluble tumor necrosis factor receptor; IFN-γ – interferon gamma; ANG1/2 = 
Angiotensin; PAI-1 = plasminogen activator inhibitor-1; DYRK2 = dual specificity tyrosine phosphorylation regulated kinase 2; 
CCNB1|P1 = cyclin B1 interacting protein 1; TDRD9 = tudor domain containing 9;ZAP70= zeta chain of T-cell receptor associated 
protein kinase 70; ARL14EP = ADP ribosylation factor like GTPase 14 effector protein;  MDC1 = mediator of DNA damage 
checkpoint 1; ADGRE3 = adhesion G protein-coupled receptor E3BPGM = bisphosphoglycerate mutase: TAP2= ATP binding 
cassette subfamily B member transporter 2; GADD45A = growth arrest and DNA damage inducible alpha; PCGF5 = polycomb 
group ring  finger 5; AHNAK = AHNAK nucleoprotein; PDCD10 = programmed cell death 10; NOP53 = ribosome biogenesis factor 
Reference Subphenotypes Comment 
Calfee C et al[33] 
[ARDS] 
Hyper-inflammatory phenotype 
versus 
Phenotype-1 
Latent class analyses based grouping based on clinical and biomarker 
data. The discriminant markers between phenotypes were IL-6; sTNFR1; 
vasopressor use; IL-8; bicarbonate 
Famous et al[32] 
[ARDS] 
Hyper-inflammatory phenotype 
versus 
Phenotype-1 
Latent class analyses based grouping based on clinical and biomarker 
data. The discriminant markers between phenotypes were IL-8; sTNFR1; 
vasopressor use; bicarbonate; minute ventilation 
Bos et al[30] 
[ARDS] 
Reactive phenotype 
versus 
Uninflamed phenotype 
Agglomerative hierarchical cluster analyses based only on biomarker data. 
The discriminant markers between phenotypes were IL-6; IFN-γ; ANG1/2; 
PAI-1 
Davenport EE et 
al[23] 
[Sepsis] 
Sepsis response signature-1 
Versus 
Sepsis response signature-2 
Agglomerative hierarchical clustering based on Ward’s method using pan 
leukocyte transcriptome using microarray. The discriminant markers 
between two phenotypes were seven genes - DYRK2, CCNB1IP1, TDRD9, 
ZAP70, ARL14EP, MDC1, and ADGRE3 
Scicluna et al[25] 
[Sepsis] 
Four molecular endotypes 
named as Mars1 to Mars4 in 
sepsis 
Agglomerative hierarchical clustering based on Ward’s method using pan 
leukocyte transcriptome using microarray. The study shows that 140-gene 
expression signature reliably stratified patients with sepsis to the four 
endotypes. The study also reports biomarkers for each endotype to 
facilitate clinical use: Mars1 = BPGM and TAP2; Mars2 = GADD45A and 
PCGF5; Mars3 = AHNAK and PDCD10; Mars4 = IFIT5, NOP53 
 
